Clinical Trials Browser

Not yet recruiting × Interventional × aflutinib × Clear all

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07348965 2026-01-16

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT07314216 2026-01-06

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07193160 2025-09-25

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1 Not yet recruiting

Advanced Non-small Cell Lung Cancer

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06483672 2024-07-03

LungBrain001

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Brain Neoplasms

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04965831 2021-07-16

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Phase 2 Not yet recruiting

Adenocarcinoma of Lung